|
Shenyang Sunshine Pharmaceutical Company Limited
Shenyang Sunshine Pharmaceutical Company Limited (SUNSHINE) is an integrated biopharmaceutical company engaged in research/development, manufacture and marketing/sales of biopharmaceutical products in China. Our recombinant, or genetically engineered, protein-based products and product candidates are designed to address large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious disease. We began operations in 1993. Currently, our principal products are EPIAO®, TPIAO®, INTEFEN® and INLEUSIN®. SUNSHINE is now one of the largest biopharmaceutical companies in China in terms of market shares, growth and profitability.
Manufacturing facilities
Our clinical and commercial manufacturing operations are based in Shenyang, China, where our Chinese current Good Manufacturing Practice, or cGMP, certified, 3,000 square meters, and state-of-the-art facility resides. Our manufacturing facilities consist of on-site bulk manufacturing, formulation, fill, finishing and packaging activities for EPIAO, TPIAO, INTEFEN and INLEUSIN. With these facilities, we are able to produce our products and product candidates for both clinical and commercial purposes. We plan to expand our plant in Shenyang to increase our manufacturing capacity and take further advantage of our favorable cost structure.
The sales and marketing team
We maintain a sales and marketing force in 18 provinces and major cities in China, including Beijing and Shanghai and Guangzhou. Our over 150 sales and marketing professionals market, and our network of approximately 80 distributors sell our principal products to healthcare providers including, based on our internal estimates, approximately 800 hospitals, clinics and dialysis centers. Our sales force in China benefits from over ten years of experience in marketing protein-based therapeutics. As a result of our history as a provider of protein therapeutics to the Chinese market, we believe our Shenyang Sunshine brand is widely recognized throughout the PRC for quality and reliability.
Research and development
Our research and development team consisted of many research personnel and medical professionals, including two PhDs, two MDs and three holders of master’s degrees and many of whom have years of experience in the healthcare and biotechnology research fields, including experience working in research institutions and hospitals and in proceeding through the SFDA drug approval process.
Our product pipeline
We focus our research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Our product pipeline, which we expect will be a key contributor to our future growth, consists of six product candidates in various stages of development. We employ a market-driven approach to our research and development efforts, and our team utilizes the latest molecular biology and biochemical techniques and technologies to develop promising product candidates. Our diversified product pipeline includes a number of next-generation protein-based therapeutics including NuPIAO, our second generation EPIAO product candidate; NuLeusin, our next-generation Inleusin product candidate; TPIAO for the treatment of ITP; a human papilloma virus, or HPV, vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. We believe that each of these product candidates, if successfully developed and approved, would address significant market opportunities. For all of our programs, we conduct extensive preclinical and clinical trials in order to generate safety and efficacy data to support a filing for approval as required to the SFDA.
|